Loading...

Ultra-LEAF™ Purified anti-human CD3 Antibody

Pricing & Availability
Clone
OKT3 (See other available formats)
Regulatory Status
RUO
Workshop
HCDM listed
Other Names
T3, CD3ε
Isotype
Mouse IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
OKT3_LEAF_021508
Human peripheral blood lymphocytes stained with LEAF™ purified OKT3, followed by anti-mouse IgG FITC
  • OKT3_LEAF_021508
    Human peripheral blood lymphocytes stained with LEAF™ purified OKT3, followed by anti-mouse IgG FITC
Cat # Size Price Quantity Check Availability Save
317325 100 µg 80€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
317326 1 mg 129€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
317347 5 mg 467€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
317348 25 mg 1127€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
317349 50 mg 1884€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
317350 100 mg 2707€
Check Availability


Need larger quantities of this item?
Request Bulk Quote

Select size of product is eligible for a 40% discount! Promotion valid until September 30, 2024. Exclusions apply. To view full promotion terms and conditions or to contact your local BioLegend representative to receive a quote, visit our webpage.

Description

CD3ε is a 20 kD chain of the CD3/T cell receptor (TCR) complex, which is composed of two CD3ε, one CD3γ, one CD3δ, one CD3ζ (CD247), and a T cell receptor (α/β or γ/δ) heterodimer. It is found on all mature T lymphocytes, NK T cells, and some thymocytes. CD3, also known as T3, is a member of the immunoglobulin superfamily that plays a role in antigen recognition, signal transduction, and T cell activation.

Product Details
Technical data sheet

Product Details

Reactivity
Human
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
0.2 µm filtered in phosphate-buffered solution, pH 7.2, containing no preservative.
Preparation
The Ultra-LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.
Concentration
The antibody is bottled at the concentration indicated on the vial, typically between 2 mg/mL and 3 mg/mL. Older lots may have also been bottled at 1 mg/mL. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C. This Ultra-LEAF™ solution contains no preservative; handle under aseptic conditions.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 2.0 µg per million cells in 100 µl volume or 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

The OKT3 monoclonal antibody reacts with an epitope on the epsilon-subunit within the human CD3 complex.

Clone OKT3 can block the binding of clones SK7 and UCHT1.4 The OKT3 antibody is able to induce T cell activation. Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen sections and activation of T cells. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 317304). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 317326) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Application References

(PubMed link indicates BioLegend citation)
  1. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
  2. Knapp W. 1989. Leucocyte Typing IV. Oxford University Press New York.
  3. Barclay N, et al. 1997. The Leucocyte Antigen Facts Book. Academic Press Inc. San Diego.
  4. Li B, et al. 2005. Immunology 116:487.
  5. Jeong HY, et al. 2008. J. Leuckocyte Biol. 83:755. PubMed
  6. Alter G, et al. 2008. J. Virol. 82:9668. PubMed
  7. Manevich-Mendelson E, et al. 2009. Blood 114:2344. PubMed
  8. Pinto JP, et al. 2010. Immunology. 130:217. PubMed
  9. Biggs MJ, et al. 2011. J. R. Soc. Interface. 8:1462. PubMed
Product Citations
  1. Bak RO, et al. 2018. Nat Protoc. 13:358. PubMed
  2. Wang J, et al. 2019. Sci Rep. 9:8445. PubMed
  3. Christopher S Garris et al. 2018. Immunity. 49(6):1148-1161 . PubMed
  4. Sun T, et al. 2019. Haematologica. 105:661. PubMed
  5. Grandclaudon M, et al. 2019. Cell. 179:432. PubMed
  6. Mancuso RV, et al. 2020. British Journal of Pharmacology. 177(12):2696-2711.. PubMed
  7. Sekine T, et al. 2020. Cell. 183:158. PubMed
  8. Hu Y, et al. 2016. J Exp Med. 213: 2759 - 2772. PubMed
  9. Hu BS, et al. 2020. Cancer Cell Int. 1.189583333. PubMed
  10. Saragovi A, et al. 2020. Elife. 9:00. PubMed
  11. Pan W, et al. 2020. JCI Insight. 5:00. PubMed
  12. Campos Carrascosa L, et al. 2020. J Immunother Cancer. 8:00. PubMed
  13. Evgin L, et al. 2020. Nat Commun. 2.671527778. PubMed
  14. Correnti CE, et al. 2020. Nat Struct Mol Biol. 27:342. PubMed
  15. Si J, et al. 2020. Cancer Cell. 38(4):551-566.e11. PubMed
  16. Glassman CR, et al. 2021. Cell. 184(4):983-999.e24. PubMed
  17. Clayton KL, et al. 2021. Cell Host Microbe. 29(3):435-447.e9. PubMed
  18. Rieder SA, et al. 2020. Cell Mol Immunol. . PubMed
  19. Yan B, et al. 2021. Sci Immunol. 6: . PubMed
  20. Zheng G, et al. 2021. Signal Transduct Target Ther. 6:236. PubMed
  21. Jung Y, et al. 2021. Nat Commun. 12:3872. PubMed
  22. Kinloch NN, et al. 2021. Nat Commun. 12:165. PubMed
  23. Chen X, et al. 2021. Theranostics. 11:3392. PubMed
  24. Xie X, et al. 2021. Front Immunol. 12:625808. PubMed
  25. Rousso-Noori L, et al. 2021. Nat Commun. 12:3615. PubMed
  26. de Haan L, et al. 2021. Int J Mol Sci. 22:. PubMed
  27. Smith CM, et al. 2021. Biochem J. 478:3331. PubMed
  28. Winheim E, et al. 2021. PLoS Pathog. 17:e1009742. PubMed
  29. Fujiwara Y, et al. 2021. Nat Commun. 12:5857. PubMed
  30. Hurov K, et al. 2021. J Immunother Cancer. 9:. PubMed
  31. Fang F, et al. 2021. Cell Rep. 37:109981. PubMed
  32. Schofield DJ, et al. 2021. MAbs. 13:1857100. PubMed
  33. Wen T, et al. 2022. Cancer Immunol Res. 10:162. PubMed
  34. Jiang J, et al. 2021. Front Immunol. 12:785549. PubMed
  35. Nicolas P, et al. 2022. J Exp Med. 219:. PubMed
  36. Yi K, et al. 2022. Front Immunol. 12:802795. PubMed
  37. Thakkar D, et al. 2022. J Immunother Cancer. 10:. PubMed
  38. Feng Y, et al. 2022. Life (Basel). 12:. PubMed
  39. Babin L, et al. 2022. Mol Cancer. 21:65. PubMed
  40. Fang F, et al. 2022. JCI Insight. 7:. PubMed
  41. Hsiue EH, et al. 2021. Science. 371:. PubMed
  42. Han K, et al. 2021. Nat Metab. 3:318. PubMed
  43. Sharma V, et al. 2021. ACR Open Rheumatol. 3:277. PubMed
  44. Rajamanickam V, et al. 2021. Cancer Immunol Res. 9:602. PubMed
  45. Liu W, et al. 2021. J Biol Chem. 297:101102. PubMed
  46. Warmuth S, et al. 2022. Oncoimmunology. 10:2004661. PubMed
  47. Gorchs L, et al. 2022. Cancers (Basel). 14:. PubMed
  48. Zhu P, et al. 2022. Cell Commun Signal. 20:121. PubMed
  49. Dahal S, et al. 2022. Retrovirology. 19:18. PubMed
  50. Liu Y, et al. 2021. Immunol Cell Biol. 99:697. PubMed
  51. Collins DR, et al. 2021. Immunity. 54:2372. PubMed
  52. Evgin L, et al. 2022. Sci Transl Med. 14:eabn2231. PubMed
  53. Reuschl AK, et al. 2022. Cell Rep. 39:110650. PubMed
  54. Chen PM, et al. 2022. Sci Adv. 8:eabo4271. PubMed
  55. Yuan X, et al. 2022. J Extracell Vesicles. 11:e12235. PubMed
  56. Natoli M, et al. 2022. J Immunother Cancer. 10:. PubMed
  57. Camviel N, et al. 2022. J Immunother Cancer. 10:. PubMed
  58. Yoon HJ, et al. 2022. Exp Mol Med. Online ahead of print. PubMed
  59. Wang J, et al. 2022. Nat Commun. 13:6866. PubMed
  60. Ren X, et al. 2022. STAR Protoc. 3:101818. PubMed
  61. Loucif H, et al. 2022. Autophagy. 18:1256. PubMed
  62. Glass MC, et al. 2022. Cell Rep. 39:110728. PubMed
  63. McMurray JL, et al. 2022. Cell Rep. 39:110858. PubMed
  64. Brog RA, et al. 2022. Cancer Immunol Res. 10:962. PubMed
  65. Vazquez-Lombardi R, et al. 2022. Immunity. 55:1953. PubMed
  66. Zhang Y, et al. 2022. J Immunol Res. 2022:9003902. PubMed
  67. Zheng X, et al. 2022. Cells. 12: . PubMed
  68. Vidard L, et al. 2023. Immun Inflamm Dis. 11:e749. PubMed
  69. Trefny MP, et al. 2023. Nat Commun. 14:86. PubMed
  70. Yen M, et al. 2022. Cell. 185:1414. PubMed
  71. Michaels YS, et al. 2022. Sci Adv. 8:eabn5522. PubMed
  72. Beck C, et al. 2023. Biomedicines. 11:. PubMed
  73. Xiong H, et al. 2023. EBioMedicine. 90:104507. PubMed
  74. Anderson W, et al. 2023. Elife. 12:. PubMed
  75. Solier S, et al. 2023. Nature. 617:386. PubMed
  76. Si W, et al. 2023. iScience. 26:106529. PubMed
  77. Issler M, et al. 2023. Methods Mol Biol. 2654:363. PubMed
  78. Jiang D, et al. 2023. Nat Commun. 14:3642. PubMed
RRID
AB_11147370 (BioLegend Cat. No. 317325)
AB_11150592 (BioLegend Cat. No. 317326)
AB_2571994 (BioLegend Cat. No. 317347)
AB_2571995 (BioLegend Cat. No. 317348)
AB_2749888 (BioLegend Cat. No. 317349)
AB_2749889 (BioLegend Cat. No. 317350)

Antigen Details

Structure
Ig superfamily, the subunits CD3γ, CD3δ, CD3ζ (CD247) and TCR (α/β or γ/δ) form the CD3/TCR complex, 20 kD
Distribution

Mature T and NK T cells, thymocyte differentiation

Function
Antigen recognition, signal transduction, T cell activation
Ligand/Receptor
Peptide antigen bound to MHC
Cell Type
NKT cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References
  1. Barclay N, et al. 1993. The Leucocyte FactsBook. Academic Press. San Diego.
  2. Beverly P, et al. 1981. Eur. J. Immunol. 11:329.
  3. Lanier L, et al. 1986. J. Immunol. 137:2501.
Gene ID
916 View all products for this Gene ID
UniProt
View information about CD3 on UniProt.org

Related FAQs

Do you guarantee that your antibodies are totally pathogen free?

BioLegend does not test for pathogens in-house aside from the GoInVivo™ product line. However, upon request, this can be tested on a custom basis with an outside, independent laboratory.

Does BioLegend test each Ultra-LEAF™ antibody by functional assay?

No, BioLegend does not test Ultra-LEAF™ antibodies by functional assays unless otherwise indicated. Due to the possible complexities and variations of uses of biofunctional antibodies in different assays and because of the large product portfolio, BioLegend does not currently perform functional assays as a routine QC for the antibodies. However, we do provide references in which the antibodies were used for functional assays and we do perform QC to verify the specificity and quality of the antibody based on our strict specification criteria.

Does BioLegend test each Ultra-LEAF™ antibody for potential pathogens?

No, BioLegend does not test for pathogens in-house unless otherwise indicated.  However, we can recommend an outside vendor to perform this testing as needed.

Have you tested this Ultra-LEAF™ antibody for in vivo or in vitro applications?

We don't test our antibodies for in vivo or in vitro applications unless otherwise indicated. Depending on the product, the TDS may describe literature supporting usage of a particular product for bioassay. It may be best to further consult the literature to find clone specific information.

Go To Top Version: 6    Revision Date: 07.16.2018

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account